Abstract:

ABSTRACT Objective: To evaluate the effect and safety of rivaroxaban in treating thromboembolism with low AT-III nephrotic syndrome（NS）. Methodology:A total of sixteen patients with AT-III-deficiency NS were diagnosed with the complications of thromboembolism by vascular ultrasound, renal venous or pulmonary artery computed tomography angiography（CTA）.They were randomly divided into two groups: rivaroxaban group treated with rivaroxaban 30mg per day (n=8) and Low Molecular Heparin（LWMH）group injected with LWMH 5000IU per 12 hours (n=8). All clinical data were collected at baseline, the 2nd and 4th week. All patients reexamined CTA at 2nd week, if thrombus didn‘t deflate obviously, the patients would do CTA at 4th week again. The primary curative effect endpoint was thrombus disappearing or volume of thrombus was reduced by 90% or more. Results: In rivaroxaban group, 5 patients and 2 patients reached the primary endpoint at the 2nd and 4th week respectively. In LWMH group, 4 patients and 3 patients reached the primary endpoint at the 2nd and 4th week respectively. But the accumulative total incidence of primary endpoint of the two groups was both 7. There was no severe hemorrhage in two groups. Conclusion: The effect and safety of rivaroxaban in treating thromboembolism with low AT-III NS was affirmative.

Key words: nephrotic syndrome, thromboembolism, AT-III, rivaroxaban, anticoagulation